Pharmacogenetics: Role in modifying drug dosage regimens

Annals of the Academy of Medicine Singapore

Volumn 29, Issue 5, 2000, Pages 628-632

  Mah, J T L ^a,b   Wong, J Y Y ^a   Lee, E J D ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Adverse drug reactions; Drug development; Efficacy; Genetic polymorphism; Genotype; Phenotype

Indexed keywords

AMIODARONE; AMITRIPTYLINE; ANTIARRHYTHMIC AGENT; ANTIDEPRESSANT AGENT; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUFURALOL; CLOMIPRAMINE; CODEINE; DEBRISOQUINE; DESIPRAMINE; ENCAINIDE; FLECAINIDE; HYDROXYAMPHETAMINE; IMIPRAMINE; INDORAMIN; ISONIAZID; MERCAPTOPURINE; METOPROLOL; MEXILETINE; NEUROLEPTIC AGENT; PERPHENAZINE; PHENFORMIN; PHENYTOIN; PROPAFENONE; PROPRANOLOL; SPARTEINE; THIORIDAZINE; TIMOLOL; UNINDEXED DRUG;

DOSE CALCULATION; DRUG EFFICACY; DRUG METABOLISM; DRUG OXIDATION; DRUG SAFETY; ETHNIC DIFFERENCE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MOLECULAR BIOLOGY; PHARMACOGENETICS; PHENOTYPE; REVIEW; TREATMENT PLANNING;

EID: 0033758420     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. Nebert D W. Pharmacogenetics: 65 candles on the cake. Pharmacogenetics 1997; 7:435-40.
2. Motulsky A G. Drug reactions, enzymes and biochemical genetics. Am Med Assn 1957; 165:835-7.
3. Vogel F. Moderne probleme der Humangenetik. Ergeb Inn Med Kinderheilkd 1959; 12:52-125.
4. Linder M W, Prough R A, Valdes R J R. Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency. Clin Chemistry 1997; 43:2:254-66.
5. Stix G. Personal pills: Genetic differences may dictate how drugs are prescribed. Sci Am 1998; 279:17-8.
6. Kalow W. Pharmacogenetics in biological perspective. Pharmacol Rev 1997; 49:369-79.
7. Persidis A. The business of pharmacogenomics. Nat Biotechnol 1998; 16:209-10.
8. Wood A J. Ethnic differences in drug disposition and response. Ther Drug Monit 1998; 20:525-6.
9. Lin J H, Lu A Y H. Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacol Rev 1997; 49:403-9.
10. Lee E J D. Genetic polymorphisms in drug metabolism. Ann Acad Med Singapore 1991; 20:56-60.
11. Evans D A P. N-acetylesterase. In: Kalow W, editor. Pharmacogenetics of Drug Metabolism. New York: Pergamon Press, 1992:95-178.
12. Creveling C R, Thakker D R. O-, N-and S-methyltransferase. In: Kauffman F C, editor. Conjugation-Deconjugation Reactions in Drug Metabolism and Toxicity. Berlin, Germany: Springer-Verlag, 1994:189-216.
13. Ayesh R, Smith R L. Genetic polymorphism in human toxicology. In: Turner P, Volans G N, editors. Recent Advances in Clinical Pharmacology and Toxicology. No.4. Edinburgh: Churchill Livingston, 1989:137-57.
14. Gonzalez F J, Skoda R C, Dimura S, Umeno M, Zanger U M, Nebert D W, et al. Characterization of the common genetic defect in humans deficient in debrisoquin metabolism. Nature 1988; 331:442-6.
15. Bowie L J, Reddy P L, Nagabhushan M, Sevigny P. Detection of alpha-thalassemias by multiplex polymerase chain reaction. Clin Chem 1994; 40:2260-6.
16. Meyer U A, Zanger U M. Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu Rev Pharmacol Toxicol 1997; 37:269-96.
17. Goldstein J A, de Morais S M F. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 1994; 4:285-99.
18. Siddoway L A, Thompson K A, McAllister C B, Wang T, Wilkinson G R, Roden D M, et al. Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences. Circulation 1987; 75:785-91.
19. Lee E J D, Jeyaseelan K. Frequency of human CYP2D6 mutant alleles in a normal Chinese population. Br J Clin Pharmacol 1994; 37:605-7.
20. Steiner E, Bertilsson L, Sawe J, Bertling I, Sjoqvist F. Polymorphic debrisoquine hydroxylation in 757 Swedish subjects. Clin Pharmacol Ther 1988; 44:431-5.
21. Lee E J D, Yeoh P N, Gong N H. Oxidation phenotyping in Chinese and Malay populations. Clin Exp Pharmacol Physiol 1988; 15:889-91.
22. th Southeast Asian Drug Metabolism Workshop. April 13-15, 1998, Kuala Lumpur, Malaysia.
23. Kupfer A, Presig R. Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man. Eur J Clin Pharmacol 1984; 26:753-9.
24. Ward S A, Goto F, Nakamura K, Jacqz E, Wilkinson G R, Branch R A. S-mephenytoin 4-hydroxylase is inherited as an autosomal recessive trait in Japanese families. Clin Pharmacol Ther 1987; 42:96-9.
25. Masimirembwa C, Bertilsson L, Johnansson I, Hasler J A, Ingelman-Sundberg M. Phenotyping and genotyping of S-mephenytoin hydroxylase (cytochrome P4502C19) in a Shona population of Zimbabwe. Clin Pharmacol Ther 1995; 57:656-61.
26. Nakamura K, Goto F, Ray W A, McAllister C B, Jacqz E, Wilkinson G R, et al. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 1985; 38:402-8.
27. Evans D A P, Manley K A, McKusick V A. Genetic control of isoniazid metabolism in man. BMJ 1960; 2:485-91.
28. Blum M, Grant D M, McBride W, Heim M, Meyer U A. Human arylamine N-acetyltransferase genes: isolation, chromosomal localization and functional expression. DNA Cell Biol 1990; 9:193-203.
29. Lee E J D, Zhao B, Moochhala S M, Ngoi S S. Frequency of mutant CYPIA1, NAT2 and GSTM1 alleles in a normal Chinese population. Pharmacogenetics 1994; 4:355-8.
30. Lee E J D, Zhao B, Choen F S. Relationship between polymorphism of N-acetyltransferase gene and susceptibility to colorectal carcinoma in a Chinese population. Pharmacogenetics 1998; 8:513-7.
31. Hassan H P, Agarwal D P, Goedde H W, Bucher H, Huland H, Brachmann W, et al. Association of N-acetyltransferase polymorphism and environmental factors with bladder carcinogens. Eur Urol 1985; 11:263-6.
32. Schultz P A. The role of genetic factors in bladder cancer. Cancer Detect Prev 1988; 11:379-88.
33. Connor A, Altorki N, Moossa A R. Tumours of colon, rectum and anus: clinical features and surgical treatment. In: Moossa A R, Robson M C, Schimpff S C, editors. Comprehensive Textbook of Oncology. Baltimore: Williams and Wilkins, 1986: 1063-79.
34. Lee E J D, Kalow W. Thiopurine S-methyltransferase activity in a Chinese population. Clin Pharmacol Ther 1993; 54:28-33.
35. Szumlanski C L, Honchel R, Scott M C, Weinshilboum R M. Human liver thiopurine methyltransferase pharmacogenetics: biochemical properties, liver-erythrocyte correlation and presence of isozymes. Pharmacogenetics 1992; 2:148-59.
36. Lennard L, Van Loon J, Lilleyman J S, Weinshilboum R M. Thiopurine pharmacogenetics in leukemia: correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations. Clin Pharmacol Ther 1987; 41:18-25.
37. Lennard L, Van Loon J, Weinshilboum R M. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther 1989; 46:149-54.